

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Rainmed Medical Limited
潤邁德醫療有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2297)

**CLARIFICATION ANNOUNCEMENT IN RELATION TO
THE INTERIM RESULTS ANNOUNCEMENT FOR
THE SIX MONTHS ENDED JUNE 30, 2025**

Reference is made to the interim result announcement for the six months ended June 30, 2025 of Rainmed Medical Limited (the “**Company**”) dated August 28, 2025 (“**2025 Interim Result Announcement**”). The Company would like to clarify that there were inadvertent errors relating to the “weighted average number of ordinary shares in issue” and the “basic and diluted loss per share” disclosed in the 2025 Interim Result Announcement. The Company hereby clarifies that the “weighted average number of ordinary shares in issue” for the six months ended June 30, 2025 of the Company is 1,180,703,000 and the “basic and diluted loss per share” for the six months ended June 30, 2025 of the Company is RMB0.03 per share.

Save as stated above, all other information in the 2025 Interim Result Announcement remains unchanged.

By Order of the Board
Rainmed Medical Limited
Huo Yunfei

Chairman of the Board and Executive Director

Hong Kong, September 28, 2025

As at the date of this announcement, the Board comprises Mr. Huo Yunfei, Mr. Zhu Zeke and Ms. Duan Jing as executive Directors, Dr. Huo Yunlong, Mr. Wang Lin and Mr. Heng Lei as non-executive Directors, and Mr. Liu Shuen Kong, Mr. Chen Xuefeng and Mr. Zhao Hui as independent non-executive Directors.